Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial 1

By Roehrborn C.G.   for the ALFUS STUDY GROUP  

Urology, Vol. 58, Iss. 6, 2001-12 ,pp. : 953-959

Elsevier

Access to resources Recommend Favorite

First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia

By Marks L.S.   Roehrborn C.G.   Gittelman M.   Kim D.   Forrest J.   Jacobs S.  

Urology, Vol. 62, Iss. 5, 2003-11 ,pp. : 888-893

Elsevier

Access to resources Recommend Favorite

Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study

By Roehrborn C.G.   Issa M.M.   Bruskewitz R.C.   Naslund M.J.   Oesterling J.E.   Perez-Marrero R.   Shumaker B.P.   Narayan P.  

Urology, Vol. 51, Iss. 3, 1998-03 ,pp. : 415-421

Elsevier

Access to resources Recommend Favorite

Comparison of a phytotherapeutic agent (permixon) with an alphablocker. (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomised international study

By Debruyne F.  

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 108-108

Elsevier

Access to resources Recommend Favorite

Comparison of a Phytotherapeutic Agent (Permixon) with an -Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study

By Debruyne F.   Koch G.   Boyle P.   Da Silva F.C.   Gillenwater J.G.   Hamdy F.C.   Perrin P.   Teillac P.   Vela-Navarrete R.   Raynaud J.-P.   For the members of the PERMAL Study Group  

European Urology, Vol. 41, Iss. 5, 2002-05 ,pp. : 497-507

Elsevier

Access to resources Recommend Favorite